1. Eli Lilly, Bristol-Myers Squibb, and other drugmakers said they are looking closely at how Spark Therapeutics plans to help payers absorb the cost of $850,000 gene therapy Luxturna. The FDA approved the drug this month for a rare type of progressive blindness. (Reuters)

2. Ipsen appointed Richard Paulson, currently Amgen’s VP and GM of oncology, as EVP and CEO of Ipsen North America. Paulson will report to Ipsen CEO David Meek.

3. The FDA could more effectively deliver drug-safety communications on social media by developing strategies around the type and frequency of its posts on digital platforms, according to a new study. (Endpoints News)

4. Roche’s multiple sclerosis drug Ocrevus received approval from the European Union for the treatment of relapsing forms of MS and primary progressive MS. Ocrevus received FDA approval last May. (Endpoints News)

5. Nestle reportedly is the top bidder for Merck KGaA’s consumer-health business, offering the German drugmaker $5 billion. (Bloomberg)